PartnershipJun 3, 2026, 06:01 AM
Aclarion Expands Nociscan Availability in Los Angeles with INI
AI Summary
Aclarion, Inc. announced an agreement with the Institute of Neuro Innovation (INI) in Los Angeles, expanding the availability of its Nociscan platform in the greater Los Angeles area. This partnership will enable INI to generate real-world evidence comparing Nociscan's chemical biomarker data with bone metabolic information from SPECT-CT, supporting more precise treatment decisions for chronic low back pain. The collaboration aligns with Aclarion's growth strategy and aims to build critical data assets for broader adoption.
Key Highlights
- Aclarion established an agreement with the Institute of Neuro Innovation (INI) in Los Angeles.
- The agreement expands the availability of Aclarion's Nociscan platform in the greater Los Angeles area.
- INI will generate real-world evidence comparing Nociscan's chemical biomarker data with SPECT-CT bone metabolic information.
- Nociscan helps physicians identify the location of chronic low back pain by quantifying chemical biomarkers.
- Nociscan has demonstrated a 97% surgical success rate when Nociscan-positive discs are treated.
- Chronic low back pain affects approximately 266 million people worldwide.
- The partnership supports Aclarion's scalable growth strategy and builds data assets for payer and provider adoption.
Price Impact
More from ACON